Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $51.00$36.00 | $7.20/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| OPTIMA457SNF | Dec 2025 | — | Janoshik Analytical | — | Confirmed | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. BPC-157 is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Hydro Research Peptides sell BPC-157?
Yes — Hydro Research Peptides currently lists BPC-157 in 1 variant starting at $36.00 ($7.20/mg).
Is Hydro Research Peptides's BPC-157 third-party tested?
Yes — Disclosed Labs has indexed 5 Certificates of Analysis for Hydro Research Peptides's BPC-157, with the most recent showing 99.1% purity. Hydro Research Peptides holds an overall trust grade of C (77/100) across all 78 COAs on file.
What is Hydro Research Peptides's trust grade for BPC-157?
Hydro Research Peptides has an overall Disclosed Labs trust grade of C (77/100), computed from 78 COAs across all peptides. The most recent BPC-157 COA was issued by Janoshik Analytical.
Where is the cheapest BPC-157?
As of the latest data, Alpha Peptides offers BPC-157 at $1.82/mg — compare with Hydro Research Peptides's listing at $7.20/mg. See the full BPC-157 price comparison.
Is BPC-157 legal to buy?
BPC-157 is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| HYDROK7Q3M2P | Dec 2025 | — | Janoshik Analytical | — | Confirmed | View |
| HYDRO9B4C1MC | Nov 2025 | 99.1% | Janoshik Analytical | — | Confirmed | View |
| BPC157-6052 | Aug 2024 | — | Janoshik Analytical | Heavy metals | Confirmed | View |
| BPC3001 | Jul 2024 | — | Janoshik Analytical | Endotoxin | Confirmed | View |